24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Tarsier Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:20
Intel steps back from Tower agreement, talks head to mediation
20:23
Defense-tech startup Tenna raises $13.5 million Seed to map the invisible battlefield
19:03
Palo Alto Networks to become Israel’s largest public company, reshaping Tel Aviv Stock Exchange
16:31
Chipmaker Tower reports record quarter as silicon photonics drives growth
More stories
Buzz
Most popular
Daily
Weekly
1
Nebius to acquire one-year-old Israeli AI startup Tavily in deal worth up to $400 million
2
Israeli defense official: “We are working on using the brain to communicate with drones”
3
“I am confident we will see a trillion-dollar Israeli company”
4
Palo Alto Networks completes CyberArk acquisition, plans Tel Aviv listing
5
Reco raises $30 million Series B to secure AI SaaS adoption across enterprises
More news
Tarsier Pharma
1 stories about Tarsier Pharma
How one female CEO overcame adversity to find a cure for Uveitis
04.02.22
|
Roni Dori
"I see us building a large company that will focus on the eye, beyond Uveitis. Our technology has tremendous potential to treat other diseases that cause blindness, and treat millions of patients," says Dr. Daphne Haim-Langford, who suffers from Uveitis and founded Tarsier Pharma